1
|
Freitas de Morais E, Siquara da Rocha LDO, de Souza Santos JL, Freitas RD, Souza BSDF, Coletta RD, Gurgel Rocha CA. Use of Three-Dimensional Cell Culture Models in Drug Assays for Anti-Cancer Agents in Oral Cancer: Protocol for a Scoping Review. J Pers Med 2023; 13:1618. [PMID: 38003933 PMCID: PMC10672016 DOI: 10.3390/jpm13111618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 09/13/2023] [Accepted: 10/19/2023] [Indexed: 11/26/2023] Open
Abstract
Advances in the development of pharmacological treatment in oral cancer require tumor models capable of simulating the complex biology of the tumor microenvironment. The spread of three-dimensional models has changed the scenery of in vitro cell culture techniques, contributing to translational oncology. Still, the full extent of their application in preclinical drug trials is yet to be understood. Therefore, the present scoping review protocol was established to screen the literature on using three-dimensional cell culture models in drug-testing assays in the context of oral cancer. This scoping review will be conducted based on the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Review guidelines (PRISMA-ScR). We will search the PubMed/Medline, Web of Science, Scopus, and Embase databases, as well as the gray literature, including peer-reviewed research articles involving 3D models applied to drug-assessment assays in oral cancer published from 1 March 2013 until 1 March 2023. Data will be charted, and findings will be described according to the predetermined questions of interest. We will present these findings in a narrative manner.
Collapse
Affiliation(s)
- Everton Freitas de Morais
- Department of Oral Diagnosis, School of Dentistry, University of Campinas (UNICAMP), Piracicaba 13414-903, SP, Brazil; (E.F.d.M.); (R.D.C.)
| | - Leonardo de Oliveira Siquara da Rocha
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, BA, Brazil; (L.d.O.S.d.R.); (J.L.d.S.S.); (B.S.d.F.S.)
- Department of Pathology and Forensic Medicine, School of Medicine, Federal University of Bahia, Salvador 40110-100, BA, Brazil
| | - John Lenon de Souza Santos
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, BA, Brazil; (L.d.O.S.d.R.); (J.L.d.S.S.); (B.S.d.F.S.)
- Department of Pathology and Forensic Medicine, School of Medicine, Federal University of Bahia, Salvador 40110-100, BA, Brazil
| | - Raíza Dias Freitas
- Department of Social and Pediatric Dentistry, School of Dentistry, Federal University of Bahia, Salvador 40110-150, BA, Brazil;
| | - Bruno Solano de Freitas Souza
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, BA, Brazil; (L.d.O.S.d.R.); (J.L.d.S.S.); (B.S.d.F.S.)
- D’Or Institute for Research and Education (IDOR), Salvador 41253-190, BA, Brazil
| | - Ricardo D. Coletta
- Department of Oral Diagnosis, School of Dentistry, University of Campinas (UNICAMP), Piracicaba 13414-903, SP, Brazil; (E.F.d.M.); (R.D.C.)
- Graduate Program in Oral Biology, School of Dentistry, University of Campinas, Piracicaba 13414-903, SP, Brazil
| | - Clarissa A. Gurgel Rocha
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador 40296-710, BA, Brazil; (L.d.O.S.d.R.); (J.L.d.S.S.); (B.S.d.F.S.)
- Department of Pathology and Forensic Medicine, School of Medicine, Federal University of Bahia, Salvador 40110-100, BA, Brazil
- D’Or Institute for Research and Education (IDOR), Salvador 41253-190, BA, Brazil
- Graduate Program in Oral Biology, School of Dentistry, University of Campinas, Piracicaba 13414-903, SP, Brazil
- Department of Propaedeutics, School of Dentistry, Federal University of Bahia, Salvador 40110-150, BA, Brazil
| |
Collapse
|
4
|
Freitas RD, Moro BLP, Pontes LRA, Maia HCM, Passaro AL, Oliveira RC, Garbim JR, Vigano MEF, Tedesco TK, Deery C, Raggio DP, Cenci MS, Mendes FM, Braga MM. The economic impact of two diagnostic strategies in the management of restorations in primary teeth: a health economic analysis plan for a trial-based economic evaluation. Trials 2021; 22:794. [PMID: 34772437 PMCID: PMC8586840 DOI: 10.1186/s13063-021-05722-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 10/13/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Different approaches have been used by dentists to base their decision. Among them, there are the aesthetical issues that may lead to more interventionist approaches. Indeed, using a more interventionist strategy (the World Dental Federation - FDI), more replacements tend to be indicated than using a minimally invasive one (based on the Caries Around Restorations and Sealants-CARS). Since the resources related to the long-term health effects of these strategies have not been explored, the economic impact of using the less-invasive strategy is still uncertain. Thus, this health economic analysis plan aims to describe methodologic approaches for conducting a trial-based economic evaluation that aims to assess whether a minimally invasive strategy is more efficient in allocating resources than the conventional strategy for managing restorations in primary teeth and extrapolating these findings to a longer time horizon. METHODS A trial-based economic evaluation will be conducted, including three cost-effectiveness analyses (CEA) and one cost-utility analysis (CUA). These analyses will be based on the main trial (CARDEC-03/ NCT03520309 ), in which children aged 3 to 10 were included and randomized to one of the diagnostic strategies (based on FDI or CARS). An examiner will assess children's restorations using the randomized strategy, and treatment will be recommended according to the same criteria. The time horizon for this study is 2 years, and we will adopt the societal perspective. The average costs per child for 24 months will be calculated. Three different cost-effectiveness analyses (CEA) will be performed. For CEAs, the effects will be the number of operative interventions (primary CEA analysis), the time to these new interventions, the percentage of patients who did not need new interventions in the follow-up, and changes in children's oral health-related quality of life (secondary analyses). For CUA, the effect will be tooth-related quality-adjusted life years (QALYs). Intention-to-treat analyses will be conducted. Finally, we will assess the difference when using the minimally invasive strategy for each health effect (∆effect) compared to the conventional strategy (based on FDI) as the reference strategy. The same will be calculated for related costs (∆cost). The discount rate of 5% will be applied for costs and effects. We will perform deterministic and probabilistic sensitivity analyses to handle uncertainties. The net benefit will be calculated, and acceptability curves plotted using different willingness-to-pay thresholds. Using Markov models, a longer-term economic evaluation will be carried out with trial results extrapolated over a primary tooth lifetime horizon. DISCUSSION The main trial is ongoing, and data collection is still not finished. Therefore, economic evaluation has not commenced. We hypothesize that conventional strategy will be associated with more need for replacements of restorations in primary molars. These replacements may lead to more reinterventions, leading to higher costs after 2 years. The health effects will be a crucial aspect to take into account when deciding whether the minimally invasive strategy will be more efficient in allocating resources than the conventional strategy when considering the management of restorations in primary teeth. Finally, patients/parents preferences and consequent utility values may also influence this final conclusion about the economic aspects of implementing the minimally invasive approach for managing restorations in clinical practice. Therefore, these trial-based economic evaluations may bring actual evidence of the economic impact of such interventions. TRIAL REGISTRATION NCT03520309 . Registered May 9, 2018. Economic evaluations (the focus of this plan) are not initiated at the moment.
Collapse
Affiliation(s)
- Raíza Dias Freitas
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Bruna Lorena Pereira Moro
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Laura Regina Antunes Pontes
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Haline Cunha Medeiros Maia
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Ana Laura Passaro
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Rodolfo Carvalho Oliveira
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Jonathan Rafael Garbim
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Maria Eduarda Franco Vigano
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | | | - Christopher Deery
- Graduate Program in Dentistry, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Daniela Prócida Raggio
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Maximiliano Sergio Cenci
- Graduate Program in Dentistry, Federal University of Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | - Fausto Medeiros Mendes
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil
| | - Mariana Minatel Braga
- Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, Lineu Prestes Avenue, 2227, São Paulo, SP, 05508000, Brazil.
| | | |
Collapse
|
5
|
Freitas RD, Dias RB, Vidal MTA, Valverde LDF, Gomes Alves Costa R, Damasceno AKA, Sales CBS, Siquara da Rocha LDO, Dos Reis MG, Soares MBP, Coletta RD, Pereira TA, Bezerra DP, Gurgel Rocha CA. Inhibition of CAL27 Oral Squamous Carcinoma Cell by Targeting Hedgehog Pathway With Vismodegib or Itraconazole. Front Oncol 2020; 10:563838. [PMID: 33312948 PMCID: PMC7703359 DOI: 10.3389/fonc.2020.563838] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Accepted: 10/15/2020] [Indexed: 12/18/2022] Open
Abstract
Oral Squamous Cell Carcinoma (OSCC) presents an important challenge for the health systems worldwide. Thus, unraveling the biological mechanisms involved in OSCC pathogenesis is essential to the discovery of new drugs with anticancer potential. The Hedgehog (HH) pathway has shown promising results as a therapeutic target both in vitro and in vivo. This study aimed to investigate the effects of vismodegib and itraconazole on the expression of Hedgehog (HH) genes (PTCH1, SMO, and GLI1), cell cycle and cell death in OSCC cells. Alamar Blue assay was used to assess the cytotoxicity of vismodegib and itraconazole in a panel of oral cancer cell lines, including CAL27. The expression of HH signaling components after treatment with vismodegib and itraconazole, at concentrations of 25 or 50 μg/ml was evaluated by qPCR. Cell cycle and apoptosis were evaluated by flow cytometry after 72 h treatment with 50 μg/ml of vismodegib or itraconazole. HH signaling was activated in OSCC cell lines CAL27, SCC4, SCC9, and HSC3. Vismodegib and itraconazole significantly reduced CAL27 cell viability after 48 h of treatment. Gene expression of PTCH1, SMO, and GLI1 decreased in response to 24 h of treatment with vismodegib or itraconazole. Furthermore, CAL27 cells exhibited alterations in morphology, cell size, and cellular granularity. An increase in the DNA fragmentation was observed after treatment and both inhibitors induced apoptosis after 72 h. In conclusion, SMO inhibitors vismodegib and itraconazole demonstrably reduced the expression of HH genes in CAL27 OSCC cell line. In addition, treatment with vismodegib and itraconazole reduced cellular viability and altered the morphology of CAL27 cells, and also induced apoptosis.
Collapse
Affiliation(s)
- Raíza Dias Freitas
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Pathology and Forensic Medicine, School of Medicine of the Federal University of Bahia, Salvador, Brazil
| | - Rosane Borges Dias
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Propaedeutics, School of Dentistry of the Federal University of Bahia, Bahia, Brazil
| | - Manuela Torres Andion Vidal
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Pathology and Forensic Medicine, School of Medicine of the Federal University of Bahia, Salvador, Brazil
| | - Ludmila de Faro Valverde
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Pathology and Forensic Medicine, School of Medicine of the Federal University of Bahia, Salvador, Brazil
| | | | | | | | | | - Mitermayer Galvão Dos Reis
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Pathology and Forensic Medicine, School of Medicine of the Federal University of Bahia, Salvador, Brazil
| | | | - Ricardo Della Coletta
- Department of Oral Diagnostics, School of Dentistry, University of Campinas, Piracicaba, Brazil
| | - Thiago Almeida Pereira
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, United States
| | | | - Clarissa Araújo Gurgel Rocha
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.,Department of Pathology and Forensic Medicine, School of Medicine of the Federal University of Bahia, Salvador, Brazil.,Department of Propaedeutics, School of Dentistry of the Federal University of Bahia, Bahia, Brazil
| |
Collapse
|
6
|
Werutsky G, Villareal-Garza C, Moreno HG, Cartagena AA, Campos-Gomez S, Reyes RO, Lence JJ, Liedke P, Reinert T, Binotto M, Dybal V, Martinez-Mesa J, Freitas RD, Nunes Filho PR, Zaffaroni F, Barrios CH. Abstract P4-12-01: Not presented. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the conference.
Citation Format: Werutsky G, Villareal-Garza C, Moreno HG, Cartagena AA, Campos-Gomez S, Reyes RO, Lence JJ, Liedke P, Reinert T, Binotto M, Dybal V, Martinez-Mesa J, Freitas RD, Nunes Filho PR, Zaffaroni F, Barrios CH. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-12-01.
Collapse
Affiliation(s)
- G Werutsky
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - C Villareal-Garza
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - HG Moreno
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - AA Cartagena
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - S Campos-Gomez
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - RO Reyes
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - JJ Lence
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - P Liedke
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - T Reinert
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - M Binotto
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - V Dybal
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - J Martinez-Mesa
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - RD Freitas
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - PR Nunes Filho
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - F Zaffaroni
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| | - CH Barrios
- Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto Nacional de Cancerología, Mexico City, Mexico; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru; Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico; Instituto Nacional de Oncología Y Radiobiología, Havana, Cuba; Breast Cancer Center, Tecnologico de Monterrey, Monterrey, Mexico; Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Centro de Pesquisa e Educação da Serra Gaúcha, Caxias do Sul, Brazil; Clínica Assitência Multidiscilinar em Oncologia, Salvador, Brazil; Centro de Pesquisas em Oncologia, Porto Alegre, Brazil
| |
Collapse
|